{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:02:49Z","timestamp":1791133369657,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.critrevonc.2022.103607","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T08:03:18Z","timestamp":1643616198000},"page":"103607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Diagnosis and treatment of therapy-related acute myeloid leukemia"],"prefix":"10.1016","volume":"171","author":[{"given":"Stephen A.","family":"Strickland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-040X","authenticated-orcid":false,"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2022.103607_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.leukres.2012.09.008","article-title":"Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?","volume":"36","author":"Aldoss","year":"2012","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"331 Flotetuzumab as salvage therapy for primary induction failure and early relapse acute myeloid leukemia","volume":"137","author":"Aldoss","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103607_bib0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103607_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.01.024","article-title":"Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease","volume":"55","author":"Annereau","year":"2017","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103607_bib0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","article-title":"Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation","volume":"13","author":"Armand","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"CPX-351 induces deep response and suppress the impact of poor prognosis mutations (TP53, ASXL1, RUNX1 and EVI1) defined by ELN-2017 in t-AML and MRC AML: a report from a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103607_bib0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2019-125579","article-title":"APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the Groupe Francophone Des My\u00e9lodysplasies (GFM)","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103607_bib0055","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103607_bib0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0065","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijerph9062075","article-title":"Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents","volume":"9","author":"Cowell","year":"2012","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103607_bib0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1309\/AJCPD85MCOHHCOMQ","article-title":"Therapy-related myeloid neoplasms","volume":"132","author":"Czader","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103607_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0080","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-na\u00efve patients with acute myeloid leukemia ineligible for intensive therapy: VIALE-A","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103607_bib0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103607_bib0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0105","series-title":"Vyxeos liposomal: daunorubicin\/cytarabine","author":"European Medicines Agency","year":"2021"},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2022.103607_bib0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/annonc\/mdt320","article-title":"Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fey","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103607_bib0115","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias","volume":"90","author":"Fianchi","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bmt.2015.338","article-title":"Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation","volume":"51","author":"Finke","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103607_bib0125","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2022.103607_bib0130","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103607_bib0135","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2019-127498","article-title":"Comprehensive analysis of genotype and prior exposures in therapy-related myeloid neoplasms (t-MNs)","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103607_bib0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021013626","article-title":"2021 update measurable residual disease in acute myeloid leukemia: european LeukemiaNet Working Party consensus document","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103607_bib0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103607_bib0160","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0165","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0170","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103607_bib0175","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103607_bib0180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V128.22.906.906","article-title":"Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large phase III trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"issue":"Suppl 15","key":"10.1016\/j.critrevonc.2022.103607_bib0185","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1200\/JCO.2017.35.15_suppl.7035","article-title":"Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): subgroup analysis of a phase III study","volume":"35","author":"Lancet","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103607_bib0190","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103607_bib0195","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2019-124383","article-title":"Outcomes in patients with therapy-related acute myeloid leukemia (t-AML) who achieved remission with CPX-351 versus 7+3: phase 3 exploratory analysis","volume":"134","author":"Lancet","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0200","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103607_bib0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tibs.2009.09.005","article-title":"WIP1 phosphatase at the crossroads of cancer and aging","volume":"35","author":"Le Guezennec","year":"2010","journal-title":"Trends Biochem. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103607_bib0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2022.103607_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","article-title":"Incidence and susceptibility to therapy-related myeloid neoplasms","volume":"184","author":"Leone","year":"2010","journal-title":"Chem. Biol. Interact."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103607_bib0220","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103607_bib0225","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103607_bib0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2019-124500","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk\/secondary acute myeloid leukemia (AML)","volume":"134","author":"Lindsley","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103607_bib0235","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103607_bib0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.beha.2017.10.001","article-title":"How can one optimize induction therapy in AML?","volume":"30","author":"Luger","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103607_bib0245","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.clml.2019.11.016","article-title":"Alternative effective and safe induction regimens for newly diagnosed acute myeloid leukemia in patients with cardiac contraindication to anthracyclines","volume":"20","author":"Marcault","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103607_bib0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103607_bib0255","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0260","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Acute Myeloid Leukemia. Version 3","author":"National Comprehensive Cancer Network","year":"2021"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103607_bib0265","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/bloodadvances.2019000955","article-title":"Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper","volume":"4","author":"Neuendorff","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103607_bib0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2003-11-3938","article-title":"Defective DNA mismatch repair in acute myeloid leukemia\/myelodysplastic syndrome after organ transplantation","volume":"104","author":"Offman","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103607_bib0275","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/gcc.10045","article-title":"Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop","volume":"33","author":"Olney","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0280","series-title":"OPDIVO\u00ae (Nivolumab) Injection, for Intravenous Use [package insert]","author":"OPDIVO\u00ae","year":"2020"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106196","article-title":"The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies","volume":"84","author":"Otoukesh","year":"2019","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0290","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1200\/JOP.19.00133","article-title":"Rapid donor identification improves survival in high-risk first-remission patients with acute myeloid leukemia","volume":"16","author":"Pagel","year":"2020","journal-title":"JCO Oncol. Pract."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103607_bib0295","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103607_bib0300","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103607_bib0305","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine +\/- bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103607_bib0310","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1080\/10428194.2020.1725503","article-title":"Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia","volume":"61","author":"Roboz","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103607_bib0315","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood-2018-99-119990","article-title":"Phase 1b\/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0320","doi-asserted-by":"crossref","unstructured":"Sallman, D.A., Asch, A.S., Kambhampati, S., Al Malki, M.M., Zeidner, J.F., Donnellan, W., et al., The first-in-class anti-CD47 antibody magrolimab combined withazacitidine is well-tolerated and effective in AML patients: phase 1b results. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition, Virtual meeting December 5\u20138, 2020.","DOI":"10.1016\/S2152-2650(21)01694-3"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103607_bib0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","article-title":"Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype","volume":"10","author":"Samra","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103607_bib0335","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103607_bib0340","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2022.103607_bib0350","series-title":"SPRYCEL\u00ae (Dasatinib) [package insert]","author":"SPRYCEL\u00ae","year":"2018"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0355","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103607_bib0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2022.103607_bib0365","series-title":"VYXEOS\u00ae (Daunorubicin and Cytarabine) Liposome for Injection, for Intravenous Us [package insert]","author":"VYXEOS\u00ae","year":"2021"},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103607_bib0370","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7540","key":"10.1016\/j.critrevonc.2022.103607_bib0375","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"The role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:44:25Z","timestamp":1760903065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":75,"alternative-id":["S1040842822000312"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103607","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of therapy-related acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103607"}}